Rankings
▼
Calendar
▼
IPSC Q3 2020 Earnings Report — Century Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
Century Therapeutics, Inc.
IPSC
Q3 2020 Earnings
Reported September 29, 2020
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Free Cash Flow
Metric
Q3 2020
Q2 2020
Q3 2019
QoQ Change
YoY Change
Revenue
$0
$0
—
—
—
Op. Income
-$13M
-$11M
—
-21.7%
—
EPS (Diluted)
$-0.31
$-0.37
—
16.2%
—
Free Cash Flow
-$14M
-$13M
—
-8.5%
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$11M
Selling & Marketing
$0
General & Administrative
$2M
SG&A Expenses
$2M
Other Expenses
$0
Operating Expenses
$13M
Cost & Expenses
$13M
OPERATING INCOME
-$13M
Interest Expense
$59.0K
Other Income/Expenses
$61.0K
INCOME BEFORE TAX
-$13M
Income Tax Expense
$0
Net Income from Continuing Ops
-$13M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$13M
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$13M
D&A
$410.0K
EBIT
-$13M
EBITDA
-$13M
EPS
-$0
EPS Diluted
-$0
marketcaparena.com
Cash Flow Statement
Item
Amount
Net Income
-$13M
Depreciation & Amortization
$410.0K
Stock-Based Compensation
$144.0K
Deferred Income Tax
$0
Other Non-Cash Items
$124.0K
Change in Working Capital
$3M
OPERATING CASH FLOW
-$9M
Capital Expenditure
-$5M
Acquisitions (Net)
$0
Purchases of Investments
-$9M
Sales/Maturities of Investments
$14M
Other Investing Activities
$0
NET CASH FROM INVESTING
$476.0K
Net Debt Issuance
$10M
Common Stock Repurchased
$0
Common Dividends Paid
$0
Other Financing Activities
-$133.0K
NET CASH FROM FINANCING
$10M
FREE CASH FLOW
-$14M
Net Change in Cash
$0
marketcaparena.com
← FY 2020
IPSC Overview
Q4 2020 →